1. Home
  2. FORR vs ACRV Comparison

FORR vs ACRV Comparison

Compare FORR & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forrester Research Inc.

FORR

Forrester Research Inc.

HOLD

Current Price

$6.43

Market Cap

105.1M

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$1.96

Market Cap

84.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FORR
ACRV
Founded
1983
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Diversified Commercial Services
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.1M
84.7M
IPO Year
1996
2022

Fundamental Metrics

Financial Performance
Metric
FORR
ACRV
Price
$6.43
$1.96
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
61.5K
794.2K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.25
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.88
$1.05
52 Week High
$11.57
$3.56

Technical Indicators

Market Signals
Indicator
FORR
ACRV
Relative Strength Index (RSI) 55.29 53.86
Support Level $5.71 $1.73
Resistance Level $6.47 $2.02
Average True Range (ATR) 0.38 0.12
MACD 0.01 -0.02
Stochastic Oscillator 58.88 31.52

Price Performance

Historical Comparison
FORR
ACRV

About FORR Forrester Research Inc.

Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: